James M. Isbell
Memorial Sloan Kettering Cancer Center, University of Virginia
Papers
5
Total Citations
382
H-Index
5
About
James M. Isbell is a leading thoracic surgeon and researcher whose work centers on advancing surgical outcomes for lung and esophageal cancers. His most impactful contribution is the landmark 2018 study on neoadjuvant nivolumab for resectable non–small cell lung cancer, which demonstrated the safety and feasibility of combining immunotherapy with pulmonary resection—a finding that has garnered nearly 300 citations and reshaped perioperative treatment paradigms. Isbell has also systematically investigated operative efficiency, showing in a 2022 study that prolonged operative time independently predicts complications after pulmonary lobectomy, providing actionable insights for surgical planning. Beyond lung cancer, he has explored quality of life after robotic-assisted esophagectomy, highlighting the patient-centered benefits of minimally invasive approaches. His recent work identifies determinants of successful minimally invasive surgery after neoadjuvant therapy, further refining patient selection. With a portfolio spanning clinical outcomes, operative safety, and survivorship, Isbell’s research bridges technical innovation and real-world patient impact, making him a key voice in modern thoracic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5